Paratek Wins Agreement With FDA on Special Protocol Assessment (SPA) for Phase 3 Study in Community-Acquired Bacterial Pneumonia (CABP) – Genetic Engineering News

most recently at Johnson & Johnson where he was the Franchise Medical Leader in anti-infectives with responsibilities for the clinical development of Levaquin (levofloxacin), Zeftera (ceftobiprole) and Doribax (doripenem). Paratek …

Leave a Reply

Your email address will not be published.

*